Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 24 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 11345702

    PGDH inhibitors and methods of making and using

    Myoforte Therapeutics, Inc. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  2. US 11339193

    CDP protein secretion inhibitors

    The Regents of the University of California · Granted May 24, 2022 · Expires May 19, 2042

    granted
  3. US 11339150

    Benzimidazole compounds as HDAC6 inhibitors

    OnKure, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  4. US 11337941

    Inhibitors and their uses

    United Kingdom Research and Innovation · Granted May 24, 2022 · Expires May 19, 2042

    granted
  5. US 11339160

    Imidazole and triazole containing bicyclic compounds as JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted May 24, 2022 · Expires May 19, 2042

    granted
  6. US 11331332

    Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted May 17, 2022 · Expires May 12, 2042

    granted
  7. US 11332470

    CXCR4 inhibitors and uses thereof

    X4 Pharmaceuticals, Inc. · Granted May 17, 2022 · Expires May 12, 2042

    granted
  8. US 11331286

    Inhibitors and their uses

    United Kingdom Research and Innovation · Granted May 17, 2022 · Expires May 12, 2042

    granted
  9. US 11332451

    RIP1 inhibitory compounds and methods for making and using the same

    Rigel Pharmaceuticals, Inc. · Granted May 17, 2022 · Expires May 12, 2042

    granted
  10. US 11332540

    Use of Circ-CDH1 inhibitors

    THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Granted May 17, 2022 · Expires May 12, 2042

    granted
  11. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted
  12. US 11325938

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted May 10, 2022 · Expires May 5, 2042

    granted
  13. US 11325936

    Sialidase inhibitors and preparation thereof

    The Regents of the University of California · Granted May 10, 2022 · Expires May 5, 2042

    granted
  14. US 11319302

    PRC1 inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  15. US 11311517

    Combination of small molecule CD-47 inhibitors with other anti-cancer agents

    Aurigene Discovery Technologies Limited · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  16. US 11311624

    Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  17. US 11306088

    CXCR4 inhibitors and uses thereof

    X4 Pharmaceuticals, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  18. US 11306095

    Use of pteridinone derivative serving as EGFR inhibitor

    East China University of Science and Technology · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  19. US 11306098

    Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors

    VENENUM BIODESIGN, LLC · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  20. US 11299492

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  21. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  22. US 11291663

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  23. US 11292847

    Methods for treating atopic dermatitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  24. US 11286307

    Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

    Takeda Pharmaceutical Company Limited · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted